3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Transitional Cell
12
Urinary Bladder Neoplasms
9
Ureteral Neoplasms
4
Urologic Neoplasms
3
Urethral Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Male Urogenital Diseases
1
Head and Neck Neoplasms
1
Female Urogenital Diseases
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Adenocarcinoma of the Bladder
1
Interventions
dodecyl maltoside
2
Magnetic Resonance Imaging
2
Electrocardiography
2
Diphenhydramine
2
Acetaminophen
2
fludarabine phosphate
1
fludarabine
1
durvalumab
1
aldesleukin
1
Tomography, X-Ray Computed
1
Respiratory Function Tests
1
Prochlorperazine
1
Positron-Emission Tomography
1
Ondansetron
1
O(6)-codeine methyl ether
1
Meperidine
1
Mastectomy, Subcutaneous
1
Loperamide
1
Interleukin-2
1
Innovar
1
Indomethacin
1
Hydroxyzine
1
Histamine Antagonists
1
Granisetron
1
Droperidol
1
Doxylamine
1
Docetaxel
1
Diphenoxylate
1
Cystoscopy
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma in Situ
×
enfortumab vedotin
×
90 days
×
Clear all
No trials found.